AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00350636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo topical gel
Description: 1 application daily to skin for 12 weeks
Study NCT01710033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tables twice daily (BID) for 28 days
Study NCT01710033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 5 mg BID
Description: CP-690,550 5 mg BID for 28 days
Study NCT01710033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 15 mg BID
Description: CP-690,550 15 mg BID for 28 days
Study NCT01710033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550 30 mg BID
Description: CP-690,550 30 mg BID for 28 days
Study NCT01356966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
Study NCT01356966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo pills PO BID for12 weeks
Study NCT01356966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folate
Description: Folate 1 mg daily for 12 weeks
Study NCT01356966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: Folate 1 mg daily for 12 weeks
Study NCT00772772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
Study NCT01550796 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: 250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
Study NCT01550796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
Study NCT02307955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: firefly
Study NCT02307955 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Study NCT02468869 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication skills training empathy skills
Study NCT02468869 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training information structuring skills
Study NCT02981342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02981342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally
Study NCT02981342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT02981342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally
Study NCT01472250 — intervention group
Intervention type: DRUG
Intervention: Clinical chemo-drugs
Description: Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel
Study NCT03820024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Feedback Messages
Description: Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
Study NCT03100370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Anodal Stimulation
Description: 2.5mA anodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study NCT01638598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo
Description: matching placebo in each dose level
Study NCT01638598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: BI 1021958
Study NCT00998309 — intervention group
Intervention type: DRUG
Intervention: Azithromycin SR
Description: Zithromax SR 2g, taking once for treatment.
Study NCT02679638 — intervention group
Intervention type: OTHER
Intervention: Factors and perceptions questionnaire
Description: A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
Study NCT02898961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin
Description: In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion.
Study NCT02679638 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview
Description: Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
Study NCT00735397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
Study NCT00994578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
Study NCT00994578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE
Description: Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
Study NCT00994578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS/COPE
Description: Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
Study NCT04225910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225Ac-PSMA
Description: all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
Study NCT00000378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: 12 week trial dose up to 200mgs
Study NCT00000378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: 12 week trial dose adjusted to therapeutic level
Study NCT02072343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No-DCCM
Study NCT02072343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCCM
Study NCT02072343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 5ml in tracheal tube
Study NCT02072343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water 10ml in tracheal tube
Study NCT00419315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Care Management
Description: Care management for alcohol dependence with a focus on pharmacotherapy
Study NCT00419315 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care included a referral to a specialty addiction treatment program.
Study NCT03616717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil
Study NCT03616717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
Study NCT04420273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SSE educational intervention
Description: Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
Study NCT04420273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control:Healthy Living
Description: Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
Study NCT01146756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
Study NCT02847988 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical Stimulation (NMES)
Description: Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
Study NCT02847988 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
Study NCT04363957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brachytherapy video
Description: Patients will watch a video that contains information about brachytherapy
Study NCT00330928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy (NIRS) Imaging
Description: Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
Study NCT00330928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravascular ultrasound (IVUS)
Description: Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
Study NCT03224871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional IL-2
Description: High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
Study NCT03224871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
Study NCT03224871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
Study NCT03224871 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
Study NCT05254561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional antigen immunotherapy
Description: Randomized double-blinded comparative effectiveness and safety clinical trial
Study NCT03094858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone with prompts
Description: Smartphone will be used to prompt randomly selected participants in intervention group to be active
Study NCT03094858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband
Description: Wristband will monitor activity of all participants
Study NCT03094858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband
Description: Wristband will monitor activity of all participants
Study NCT03094858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
Study NCT03859739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8558
Description: Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
Study NCT05709522 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurocognitive tools
Description: Neurocognitve and psychological tools
Study NCT01158144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
Study NCT01158144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel/Carboplatin
Description: Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
Study NCT00390481 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: EC-IC Bypass in the COSS study
Description: EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
Study NCT01638208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
Study NCT03467490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DED self-management
Description: This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
Study NCT00975819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: liquid dosing based on trough levels
Study NCT01920893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for dupilumab)
Description: Solution for injection; Subcutaneous injection.
Study NCT01920893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection; Subcutaneous injection.
Study NCT01920893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Nasal spray, 2 actuations in each nostril twice daily.
Study NCT01920893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Nasal spray, 2 actuations in each nostril twice daily.
Study NCT03100370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Cathodal Stimulation
Description: 2.5mA cathodal tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study NCT01683513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh agonist +1500E hCG
Description: ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
Study NCT02252601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFDT test
Study NCT02252601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFDT test
Study NCT02252601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure tone Audiogram
Study NCT01372501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobarrier Liner
Description: Medical device placed endoscopically in the duodenum
Study NCT00528814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Hand Sanitizer
Description: Active Hand Sanitizer
Study NCT03030092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximal Strength Training
Description: leg pres and abduction exercises
Study NCT01758367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deciatbine(DAC)
Study NCT00983944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV
Study NCT00983944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Description: Given IV or orally
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV or orally
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV or orally
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV or orally
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV or orally
Study NCT03100370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tsDCS-Sham Stimulation
Description: 2.5mA sham tsDCS over cervical spine for 20 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder.
Study NCT00983944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV or orally
Study NCT02345811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire
Description: silicone-hydrogel contact lens
Study NCT02345811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: contact lens
Study NCT03366376 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT with hippocampus-sparing and SIB
Description: Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy
Study NCT03633487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 1200 mg ER Bi-Layer tablet
Study NCT00660530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate Chewable Product
Description: Lanthanum carbonate 1 g to be chewed, three times daily with meals